GlassScriptPhysician profile
Christina Diane Holt
NPI 1639940786
$975.88
in general payments reported to CMS, 2019-2025
16 companies · $621 in 2025
The $621 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $355 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $134.15 | 2024-2025 | Airsupra, Farxiga |
| Vanda Pharmaceuticals INC. | $120.87 | 2024-2025 | Fanapt, Hetlioz |
| Xeris Pharmaceuticals, INC. | $115.76 | 2024-2025 | Gvoke Hypopen |
| Abbvie INC. | $111.19 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $92.05 | 2025 | Cobenfy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.81 | 2025 | Xifaxan |
| Ardelyx, INC. | $51.32 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $50.34 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $48.30 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.39 | 2025 | Caplyta |
| Aimmune Therapeutics, INC. | $41.09 | 2025 | Zenpep |
| Axsome Therapeutics, INC. | $40.09 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.16 | 2025 | |
| Lundbeck LLC | $19.67 | 2025 | Vyepti |
| Viatris Specialty LLC | $18.81 | 2025 | Yupelri |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $14.88 | 2025 | Inceptiv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.